Narjust Florez: Discharge is the time when patients are most vulnerable
Narjust Florez shared in Twitter:
“Discharge is the time when patients are most vulnerable.
- A new normal starts.
- An unimaginable new number of pills that need to fit in schedules.
- All pills look the same, white and round.
- From support to loneliness.
I will NEVER see discharges the same way.”
Source: Narjust Florez/Twitter
Narjust Florez is the Associate Director of the Cancer Care Equity Program and a thoracic medical oncologist at the Dana-Farber Brigham Cancer Center. She is the principal investigator of the Sexual Health Assessment in Women with Lung Cancer (SHAWL) Study, the largest study to date evaluating sexual dysfunction in women with lung cancer. She received the 2020 Rising Star award by the LEAD National Conference for women in hematology and oncology. In addition, Dr. Florez founded the Florez Lab in 2019. The laboratory focuses on lung cancer, social justice issues in medicine, and medical education.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023